KBroVet-CA1 is an antiepileptic for use in dogs only. The chewable tablets are flavored, contain potassium bromide (KBr), and are available in two doses (250mg and 500mg). This drug should not be used in animals with a history of hypersensitivity to bromide. KBroVet-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness.
KBroVet-CA1 is indicated for the control of seizures associated with idiopathic epilepsy in dogs. Not for human use. Not for use in cats. Contact a physician in case of accidental ingestion by humans. Increased appetite, weight gain, vomiting/regurgitation and sedation were the most common side effects. Dogs receiving KBroVet-CA1 should be carefully monitored when changing diets, administering chloride-containing IV fluids, and administering concurrent medications. Careful monitoring is important in dogs that have a condition that may cause difficulty maintaining electrolyte balance. Animals with decreased renal function may be predisposed to bromide toxicosis. Some dogs may experience epileptic episodes that are unresponsive or refractory to KBr monotherapy and KBr alone may not be adequate treatment for every dog with idiopathic epilepsy. The safe use of KBroVet-CA1 has not been evaluated in dogs that are intended for breeding, or that are pregnant or lactating. The safe use of KBr in neonates and young animals has not been established.
See full Prescribing Information.Consult your veterinarian and follow your pet's prescription for specific dosing instructions for your pet. Store at controlled room temperature 20–25°C (68–77°F). KBroVet-CA1 may be dosed with or without food.